Ownership and insider activity for TG Therapeutics, Inc. (TGTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Price
| Price | $55.85 |
| Market Cap | $8.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-10 | Charney Laurence N | S-Sale | 5,000 | $275K |
| 2026-08-06 | Charney Laurence N | G-Gift | 5,100 | |
| 2026-08-07 | Charney Laurence N | G-Gift | 500 | |
| 2026-08-07 | Charney Laurence N | G-Gift | 450 | |
| 2026-06-11 | Lonial Sagar | A-Award | 8,325 | |
| 2026-06-11 | HUME DANIEL | A-Award | 8,325 | |
| 2026-06-11 | Hoberman Kenneth | A-Award | 8,325 | |
| 2026-06-11 | Echelard Yann | A-Award | 8,325 | |
| 2026-06-11 | Charney Laurence N | A-Award | 8,325 | |
| 2026-01-28 | Charney Laurence N | G-Gift | 30,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.0M | $56.7M | $42.0M | $112.6M | $553.4M | $298.9M | $102.3M | $92.9M | $179.9M | $79.1M |
| Short-term Investments | $19.9M | $28.0M | $26.8M | $27.8M | $52.0M | $15.9M | $59.4M | $124.6M | $131.1M | $62.8M |
| Receivables | $83852 | $108468 | $95000 | 0 | 0 | $1.4M | 0 | $51.1M | $129.2M | $305.6M |
| Inventory | $5.6M | $7.9M | $9.7M | 0 | 0 | 0 | 0 | $39.8M | $110.5M | $125.6M |
| Total Current Assets | $50.9M | $93.3M | $79.0M | $149.2M | $611.7M | $331.0M | $168.3M | $317.9M | $566.4M | $630.8M |
| Property, Plant & Equipment | $2.4M | $2.7M | $2.5M | $11.8M | $11.8M | $11.1M | $10.8M | $8.1M | $7.2M | $6.3M |
| Goodwill | $799391 | $799391 | $799000 | $799000 | $799000 | $799000 | $799000 | $799000 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $54.8M | $97.4M | $83.6M | $163.0M | $625.6M | $379.6M | $193.6M | $329.6M | $577.7M | $1.06B |
| Accounts Payable | $15.3M | $25.9M | $36.4M | 0 | 0 | 0 | 0 | 0 | 0 | $107.5M |
| Short-term Debt | $68875 | $127614 | $67000 | 0 | $22.2M | $975000 | 0 | 0 | 0 | $1.0M |
| Total Current Liabilities | $16.9M | $28.0M | $38.9M | $84.4M | $87.6M | $65.4M | $53.2M | $53.7M | $90.7M | $153.8M |
| Long-term Debt | 0 | 0 | 0 | $29.0M | $7.7M | $66.8M | $71.1M | $100.1M | $244.4M | $252.7M |
| Total Liabilities | $54.8M | $97.4M | $59.6M | $124.4M | $106.3M | $142.5M | $135.0M | $169.1M | $355.3M | $415.2M |
| Retained Earnings | -$236.4M | -$354.9M | -$528.3M | -$701.2M | -$980.6M | -$1.33B | -$1.53B | -$1.55B | -$1.53B | -$1.08B |
| Total Equity | $35.9M | $67.0M | $24.0M | $38.6M | $519.4M | $237.2M | $58.6M | $160.5M | $222.4M | $648.0M |
| Total Debt | $68875 | $127614 | $67000 | $40.8M | $42.0M | $79.0M | $83.1M | $110.8M | $253.7M | $260.7M |
| Net Debt | -$44.9M | -$84.7M | -$68.7M | -$99.6M | -$563.5M | -$235.7M | -$78.6M | -$106.7M | -$57.3M | $118.8M |
| Working Capital | $34.0M | $65.4M | $40.2M | $64.7M | $524.2M | $265.6M | $115.1M | $264.2M | $475.7M | $477.0M |
Financial Health
| Debt / Equity | 1.25 |
| Current Ratio | 4.27 |
Profitability
| Gross Margin | 82.36% |
| Operating Margin | 17.05% |
| Net Margin | 55.22% |
Related companies: ACLX · ALKS · ARWR · CRSP · IMVT · KRYS · KYMR
Explore sector: Healthcare · Biotechnology
More sections of TGTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks